Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

En forskningsstudie för att se hur mycket CagriSema sänker blodsockret och kroppsvikten jämfört med placebo hos personer med typ 2-diabetes som behandlas med kost och träning (REIMAGINE 1)

28 september 2026 uppdaterad av: Novo Nordisk A/S

Effekt och säkerhet av samtidigt administrerad Cagrilintide och Semaglutid (CagriSema) s.c. i doser 2,4 mg/2,4 mg och 1,0 mg/1,0 mg en gång i veckan kontra placebo hos deltagare med typ 2-diabetes otillräckligt kontrollerad på kost och träning

This study will look at how much CagriSema helps participants with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a "dummy" medicine (also called "placebo") that has no effect on the body. Participants will get either CagriSema or "dummy" medicine. Which treatment participants get is decided by chance. For each participant, the study will last for about one year.

Studieöversikt

Studietyp

Interventionell

Inskrivning (Faktisk)

189

Fas

  • Fas 3

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • California
      • Huntington Park, California, Förenta staterna, 90255
        • Nat Res Inst Huntington Park
      • Northridge, California, Förenta staterna, 91325
        • Valley Clinical Trials, Inc.
      • Santa Ana, California, Förenta staterna, 92701
        • Southern California Dermatology
    • Florida
      • Hollywood, Florida, Förenta staterna, 33024
        • Encore Medical Research LLC
      • Orlando, Florida, Förenta staterna, 32819
        • Headlands Research Orlando
      • Weston, Florida, Förenta staterna, 33331
        • Encore Medical Research of Weston
    • Kansas
      • Newton, Kansas, Förenta staterna, 67114
        • Alliance for Multispec Res
    • Massachusetts
      • Boston, Massachusetts, Förenta staterna, 02115
        • Brigham & Women's Hospital
    • Michigan
      • Troy, Michigan, Förenta staterna, 48098
        • Arcturus HC PLC Troy Med Res
    • New York
      • West Seneca, New York, Förenta staterna, 14224
        • Southgate Medical Group, LLP
    • Oregon
      • Portland, Oregon, Förenta staterna, 97210
        • Summit Research Network Oregon Inc.
    • Tennessee
      • Kingsport, Tennessee, Förenta staterna, 37660
        • Holston Medical Group
    • Texas
      • Amarillo, Texas, Förenta staterna, 79124
        • Amarillo Medical Specialists
      • Austin, Texas, Förenta staterna, 78704
        • Elligo Clin Res Centre
      • Brownsville, Texas, Förenta staterna, 78526
        • Headlands Research Brownsville
      • Dallas, Texas, Förenta staterna, 75230
        • Velocity Clinical Res-Dallas
      • San Antonio, Texas, Förenta staterna, 78233
        • Northeast Clinical Research of San Antonio
      • Shavano Park, Texas, Förenta staterna, 78231
        • Consano Clinical Research, LLC
      • Sugar Land, Texas, Förenta staterna, 77479
        • Sugar Lakes Family Practice PA
      • Weslaco, Texas, Förenta staterna, 78596
        • Valley Diab. & Endo Comp Ctr
    • Virginia
      • Newport News, Virginia, Förenta staterna, 23606
        • TPMG Clinical Research
      • Bergamo, Italien, 24127
        • Azienda Ospedaliera Papa Giovanni XXIII
      • Catanzaro, Italien, 88100
        • Policlinico Mater Domini Università di Catanzaro
      • Milan, Italien, 20132
        • IRCCS Ospedale San Raffaele Milano
      • Roma, Italien, 00161
        • Azienda Ospealiero Universitaria Policlinico Umberto I
    • Beijing Municipality
      • Beijing, Beijing Municipality, Kina, 100853
        • Chinese People's Liberation Army General Hospital-Endocrinology
    • Jiangsu
      • Nanjing, Jiangsu, Kina, 210011
        • The Second Affiliated Hospital of Nanjing Medical University-Endocrinology
      • Zhenjiang, Jiangsu, Kina, 212001
        • The Affiliated Hospital of Jiangsu University-Endocrinology
    • Shandong
      • Ji'Nan, Shandong, Kina, 250000
        • Jinan Central Hospital
      • Jinan, Shandong, Kina, 250000
        • Jinan Central Hospital
      • Bialystok, Polen, 15-351
        • Osteo-Medic s.c. A. Racewicz, J. Supronik
      • Bialystok, Polen, 15-797
        • Renew Clinic Sp. z o.o.
      • Lodz, Polen, 90-338
        • Centrum Terapii Wspolczesnej J.M. Jasnorzewska S.K.A.
      • Warsaw, Polen, 02-507
        • Panstwowy Instytut Medyczny Ministerstwa Spraw Wewnetrznych I Administracji
      • Warsaw, Polen, 00-710
        • NBR Polska Tomasz Klodawski
      • Zamość, Polen, 22-400
        • Velocity Nova Sp. z o.o.
    • Podkarpackie Voivodeship
      • Rzeszów, Podkarpackie Voivodeship, Polen, 35-055
        • Centrum Medyczne Medyk Sp. z o.o.
      • Al Ahsa, Saudiarabien, 36428
        • King Abdulaziz Hospital-Al Ahsa-National Guard
      • Jeddah, Saudiarabien, 21423
        • National Guard Hospital - Jeddah
      • Riyadh, Saudiarabien, 11525
        • King Fahad Medical City
      • Riyadh, Saudiarabien, 12372
        • King Khaled University Hospital,King Saud Univ. Med. City
      • Riyadh, Saudiarabien, 12769
        • King Salman Bin Abdulaziz Hospital
      • Belgrade, Serbien, 11080
        • Clinical Hospital Center Bezanijska Kosa
      • Belgrade, Serbien, 11080
        • Clinical Hospital Centre Zemun
      • Belgrade, Serbien, 11000
        • CHC Zvezdara, Clinical department for endocrinology
      • Zaječar, Serbien, 19000
        • Policlinic for diabetes
      • Budapest, Ungern, 1032
        • Szent Margit Rendelőintézet Nonprofit Kft.
      • Budapest, Ungern, 1102
        • PVN Kutató Kft.
    • Hajdú-Bihar
      • Debrecen, Hajdú-Bihar, Ungern, 4025
        • Belinus Bt.
    • Szabolcs-Szatmar Varmegye
      • Nyíregyháza, Szabolcs-Szatmar Varmegye, Ungern, 4405
        • Borbánya Praxis E.Ü. Kft.

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Male or female
  • Age 18 years or above at the time of signing the informed consent
  • Diagnosed with type 2 diabetes >=30 days before screening
  • HbA1c 7.0-9.5 percent (53-80 millimoles per mole [mmol/mol]) (both inclusive) as determined by central laboratory at screening
  • Body mass index (BMI) >=23 kilograms per square meter (kg/m^2) at screening. BMI will be calculated in the electronic case report form (eCRF) based on height and body weight at screening

Exclusion Criteria:

  • Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using a highly effective contraceptive method
  • Renal impairment with estimated Glomerular Filtration Rate less than 30 milliliter per minute per 1.73 square meter (ml/min/1.73 m^2) as determined by central laboratory at screening
  • Treatment with any medication for the indication of diabetes or obesity within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed
  • History of use of any injectable therapy for diabetes or obesity. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed
  • Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Fyrdubbla

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Aktiv komparator: CagriSema Dose 2

Participants will receive once-weekly subcutaneous (s.c) injections of CagriSema (cagrilintide and semaglutide) at escalating doses every week in 16-week dose escalation period until target dose (dose 2) of CagriSema (cagrilintide and semaglutide) is achieved and maintained up to 24 weeks.

Participants will receive once-weekly cagrilintide subcutaneously.

Participants will receive once-weekly semaglutide subcutaneously.

Placebo-jämförare: Placebo Dose 2

Participants will receive once-weekly s.c injection of placebo matched to Cagrisema (cagrilintide and semaglutide) dose 2 for 40 weeks.

Participants will receive placebo matched to cagrilintide and semaglutide subcutaneously.

Aktiv komparator: Cagrisema Dose 1

Participants will receive once-weekly subcutaneous (s.c) injections of CagriSema (cagrilintide and semaglutide) at escalating doses every week in 8-week dose escalation period until target dose (dose 1) of CagriSema (cagrilintide and semaglutide) is achieved and maintained up to 32 weeks.

Participants will receive once-weekly cagrilintide subcutaneously.

Participants will receive once-weekly semaglutide subcutaneously.

Placebo-jämförare: Placebo Dose 1

Participants will receive once-weekly s.c injection of placebo matched to Cagrisema (cagrilintide and semaglutide) dose 1 for 40 weeks.

Participants will receive placebo matched to cagrilintide and semaglutide subcutaneously.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change in glycated haemoglobin (HbA1c)
Tidsram: From baseline (week 0) to end of treatment (week 40)

Measured as percentage (%)-points.

From baseline (week 0) to end of treatment (week 40)

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Relative change in body weight
Tidsram: From baseline (week 0) to end of treatment (week 40)

Measured in %.

From baseline (week 0) to end of treatment (week 40)
Number of participants who achieve greater than or equal to (>=) 10% body weight reduction
Tidsram: From baseline (week 0) to end of treatment (week 40)

Measured as count of participants.

From baseline (week 0) to end of treatment (week 40)
Number of participants who achieve >=15% body weight reduction
Tidsram: From baseline (week 0) to end of treatment (week 40)

Measured as count of participants.

From baseline (week 0) to end of treatment (week 40)
Number of participants who achieve HbA1c target values of less than (<) 7.0% (<53 millimoles per mole [mmol/mol])
Tidsram: At end of treatment (week 40)

Measured as count of participants.

At end of treatment (week 40)
Number of participants who achieve HbA1c target values of less than or equal to (<=) 6.5% (<= 48 mmol/mol)
Tidsram: At end of treatment (week 40)

Measured as count of participants.

At end of treatment (week 40)
Change in Fasting Plasma Glucose (FPG)
Tidsram: From baseline (week 0) to end of treatment (week 40)

Measured in millimoles per liter (mmol/L).

From baseline (week 0) to end of treatment (week 40)
Number of participants who achieve >=5% body weight reduction
Tidsram: From baseline (week 0) to end of treatment (week 40)

Measured as count of participants.

From baseline (week 0) to end of treatment (week 40)
Number of participants who achieve >=20% body weight reduction
Tidsram: From baseline (week 0) to end of treatment (week 40)

Measured as count of participants.

From baseline (week 0) to end of treatment (week 40)
Change in waist circumference
Tidsram: From baseline (week 0) to end of treatment (week 40)

Measured in centimeters (cm).

From baseline (week 0) to end of treatment (week 40)
Change in systolic blood pressure (SBP)
Tidsram: From baseline (week 0) to end of treatment (week 40)

Measured in millimeters of mercury (mmHg).

From baseline (week 0) to end of treatment (week 40)
Change in diastolic blood pressure (DBP)
Tidsram: From baseline (week 0) to end of treatment (week 40)

Measured in mmHg.

From baseline (week 0) to end of treatment (week 40)
Ratio to baseline in high sensitivity C-reactive protein (hsCRP)
Tidsram: From baseline (week 0) to end of treatment (week 40)

Measured as ratio.

From baseline (week 0) to end of treatment (week 40)
Ratio to baseline in lipids: Total cholesterol
Tidsram: From baseline (week 0) to end of treatment (week 40)

Measured as ratio.

From baseline (week 0) to end of treatment (week 40)
Ratio to baseline in lipids: High-density lipoprotein (HDL) cholesterol
Tidsram: From baseline (week 0) to end of treatment (week 40)

Measured as ratio.

From baseline (week 0) to end of treatment (week 40)
Ratio to baseline in lipids: Low-density lipoprotein (LDL) cholesterol
Tidsram: From baseline (week 0) to end of treatment (week 40)

Measured as ratio.

From baseline (week 0) to end of treatment (week 40)
Ratio to baseline in lipids: Very low-density lipoprotein (VLDL) cholesterol
Tidsram: From baseline (week 0) to end of treatment (week 40)

Measured as ratio.

From baseline (week 0) to end of treatment (week 40)
Ratio to baseline in lipids: Triglycerides
Tidsram: From baseline (week 0) to end of treatment (week 40)

Measured as ratio.

From baseline (week 0) to end of treatment (week 40)
Ratio to baseline in lipids: Free fatty acids
Tidsram: From baseline (week 0) to end of treatment (week 40)

Measured as ratio.

From baseline (week 0) to end of treatment (week 40)
Ratio to baseline in lipids: Non-HDL cholesterol
Tidsram: From baseline (week 0) to end of treatment (week 40)

Measured as ratio.

From baseline (week 0) to end of treatment (week 40)
Number of participants who achieve type 2 diabetes (T2D) remission (HbA1c <6.5% and no antidiabetic medication)
Tidsram: At end of study (week 52)

Measured as count of participants.

At end of study (week 52)
Ratio to baseline in oral glucose tolerance test (OGTT) based oral glucose disposition index (DIo)
Tidsram: From baseline (week 0) to end of treatment (week 40)

Measured as ratio.

From baseline (week 0) to end of treatment (week 40)
Change in experienced level of energy as measured by the SF-36v2 Health Survey Acute (SF-36v2) Vitality score
Tidsram: From baseline (week 0) to end of treatment (week 40)

Measured as score points. SF-36v2 Acute measures Health-Related Quality of Life (HRQoL). The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 Acute scores are norm-based scores, that is. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10.

Higher scores indicate better functional health and well-being. The vitality score range is from 25.6 to 69.1.

From baseline (week 0) to end of treatment (week 40)
Change in SF-36v2 score: Physical Component Summary score
Tidsram: From baseline (week 0) to end of treatment (week 40)

Measured as score points. SF-36v2 Acute measures HRQoL. The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 Acute scores are norm-based scores, that is. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10. Higher scores indicate better functional health and well-being. The score range for physical component summary is 6.1 to 79.7.

From baseline (week 0) to end of treatment (week 40)
Change in SF-36v2 score: Mental Component Summary score
Tidsram: From baseline (week 0) to end of treatment (week 40)

Measured as score points. SF-36v2 Acute measures HRQoL. The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 Acute scores are norm-based scores, that is. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10. Higher scores indicate better functional health and well-being. The score range for mental component summary score is -3.8 to 78.7.

From baseline (week 0) to end of treatment (week 40)
Change in Diabetes Treatment Satisfaction Questionnaire (DTSQ) score
Tidsram: From baseline (week 0) to end of treatment (week 40)

Measured as score points. DTSQs measures treatment satisfaction and diabetes-specific quality of life. The measure consists of 8 items yielding 1 global score and 2 single item scores. Higher scores on the global score indicate greater satisfaction with treatment. Lower scores on the single-item scores indicate BG levels closer to the ideal, while higher scores indicate problems. Single-item scores (score range): Perceived frequency of hyperglycaemia (0-6), Perceived frequency of hypoglycaemia (0-6). Global score (score range): Total Treatment Satisfaction (0-36).

From baseline (week 0) to end of treatment (week 40)
Change in leptin
Tidsram: From baseline (week 0) to end of treatment (week 40)

Measured in nanograms per milliliter (ng/mL).

From baseline (week 0) to end of treatment (week 40)
Change in soluble leptin receptor
Tidsram: From baseline (week 0) to end of treatment (week 40)

Measured in ng/mL.

From baseline (week 0) to end of treatment (week 40)
Number of Treatment Emergent Adverse Events (TEAEs)
Tidsram: From baseline (week 0) to end of treatment +7 weeks (week 47)

Measured as count of events.

From baseline (week 0) to end of treatment +7 weeks (week 47)
Number of clinically significant hypoglycaemic episodes (level 2) (<3.0 mmol (54 milligrams per deciliter [mg/dL]), confirmed by blood glucose (BG) meter
Tidsram: From baseline (week 0) to end of treatment +7 weeks (week 47)

Measured as count of episodes.

From baseline (week 0) to end of treatment +7 weeks (week 47)
Number of severe hypoglycaemic episodes (level 3): hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery, with no specific glucose threshold
Tidsram: From baseline (week 0) to end of treatment + 7 weeks (week 47)

Measured as count of episodes.

From baseline (week 0) to end of treatment + 7 weeks (week 47)

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Studierektor: Clinical Transparency (dept. 2834), Novo Nordisk A/S

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

19 mars 2024

Primärt slutförande (Faktisk)

1 oktober 2025

Avslutad studie (Faktisk)

22 december 2025

Studieregistreringsdatum

Först inskickad

15 mars 2024

Först inskickad som uppfyllde QC-kriterierna

15 mars 2024

Första postat (Faktisk)

21 mars 2024

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

30 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

28 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • NN9388-4895
  • 2022-502677-42 (Annan identifierare: European Medical Agency (EMA))
  • U1111-1283-0404 (Annan identifierare: World Health Organization (WHO))

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

According to the Novo Nordisk disclosure commitment on novonordisk-trials.com.

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera